Palliative Split-Course pelvic radiotherapy for symptomatic cervical cancer

Main Article Content

Eter Natelauri
Krystyna Kiel
Tea Natelauri
Tinatin Liluashvili
Tornike Badzgaradze
Jarji Batsikadze
Zurabi Tcheishvili
Nika Targaladze


Objective: Palliative pelvic RT effectively relieves significant health issues such as bleeding from the tumor, pain, discharge, or mass effect on the rectum genitourinary tract vessels and nerves in cervical cancer patients. There is no exact conclusion about an ideal palliative radiation treatment dose regimen. Thus we share the results of a commonly used split-course palliative pelvic RT regimen in our hospital.

Material and Methods: For a retrospective study, 9 patients records treated between 2015 and 2019 were reviewed. The dose of prescribed irradiation for the target was 20Gy in 5 daily fractions. An additional 20Gy in 5 fractions was delivered after a 2-week time for recovery. Symptomatic improvement and treatment-related toxicity during and after RT were assessed from handwritten clinician reports.

Results: Vast majority of patients enduring, and rapid symptomatic improvement was observed. Grade 3 to 5 treatment toxicity was not examined. Maximum acute toxicity was grade 1 GI or GU toxicity in 4 patients and G2 in two patients. Three patients had no acute side effects. All patients had complete symptom remission after treatment, one patient did not complete the second course of therapy due to deteriorating performance status, but local symptom relief was achieved.

Conclusion: Split course regimen effectively improved symptoms without significant toxicity. The integrated 2-week break allowed doctors to assess patients for increased dose palliative radiation and balanced therapeutic benefits with possible adverse effects. This regimen is a reasonable strategy for patients who do not tolerate definitive treatment.


Download data is not yet available.

Article Details

How to Cite
Natelauri, E., Kiel, K., Natelauri, T., Liluashvili, T., Badzgaradze, T., Batsikadze, J., Tcheishvili, Z., & Targaladze, N. (2022). Palliative Split-Course pelvic radiotherapy for symptomatic cervical cancer. Medical Science and Discovery, 9(4), 214–219.
Research Article
Received 2022-03-13
Accepted 2022-04-02
Published 2022-04-08


Cervical cancer.

Aboyeji PA, Ijaiya MD, Jimoh AG. Knowledge, attitude and practice of cervical smear as a screening procedure for cervical cancer in Ilorin, Nigeria. Tropical journal of obstetrics and gynaecology. 2004;21(2):114-7. DOI:

O. Ajayi, IF Adewole I. Determinants of utilisation of cervical cancer screening facility in a low socio-economic setting in Nigeria. Journal of Obstetrics and Gynaecology. 1998 Jan 1;18(2):154-8. DOI:

Asonganyi E, Vaghasia M, Rodrigues C, Phadtare A, Ford A, Pietrobon R, Atashili J, Lynch C. Factors affecting compliance with clinical practice guidelines for pap smear screening among healthcare providers in africa: systematic review and meta-summary of 2045 individuals. PloS one. 2013 Sep 12;8(9):e72712. DOI:

Ayinde OA, Omigbodun AO, Ilesanmi AO. Awareness of cervical cancer, Papanicolaou's smear and its utilisation among female undergraduates in Ibadan. African Journal of Reproductive Health. 2004 Dec 1:68-80. DOI:

Bradford LE, Goodman AN. Cervical cancer screening and prevention in low-resource settings. Clinical Obstetrics and Gynecology. 2013 Mar 1;56(1):76-87. DOI:

Bukar M. Determinants of utilization of papanicolaou smear among outpatient clinic attendees in north-eastern Nigeria. African Journal of Medicine and Medical Sciences. 2012;41(2):183-9.

Hyacinth HI, Adekeye OA, Ibeh JN, Osoba T. Cervical cancer and pap smear awareness and utilization of pap smear test among Federal civil servants in North Central Nigeria.

Mukakalisa I, Bindler R, Allen C, Dotson J. Cervical cancer in developing countries: effective screening and preventive strategies with an application in Rwanda. Health care for women international. 2014 Sep 1;35(7-9):1065-80. DOI:

Ikechebelu JI, Onyiaorah IV, Ugboaja JO, Anyiam DC, Eleje GU. Clinicopathological analysis of cervical cancer seen in a tertiary health facility in Nnewi, south-east Nigeria. Journal of Obstetrics and Gynaecology. 2010 Apr 1;30(3):299-301. DOI:

Sasieni P, Castanon A. NHSCSP Audit of invasive cervical cancer: national report 2007–2011. InNHSCSP 2012.

Umezulike AC, Tabansi SN, Ewunonu HA, Nwana EJ. Epidemiological characteristics of carcinoma of the cervix in the Federal capital Territory of Nigeria. Nigerian journal of clinical practice. 2007 Sep 11;10(2):143-6.

Koh WJ, Abu-Rustum NR, Bean S. NCCN guidelines version 5.2019 in cervical cancer. NCCN (National Comprehensive Cancer Network). 2019;17(1):64-84. DOI:

WHO. Accessed 11 June 2012

Chow E, Wong R, Hruby G, Connolly R, Franssen E, Fung KW, Andersson L, Schueller T, Stefaniuk K, Szumacher E, Hayter C. Prospective patient-based assessment of effectiveness of palliative radiotherapy for bone metastases. Radiotherapy and Oncology. 2001 Oct 1;61(1):77-82. DOI:

Kirkbride P, Barton R (1999) Palliative radiation therapy. J Palliat Med 2(1):87–97 DOI:

Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Practice & Research Clinical Obstetrics & Gynaecology. 2001 Apr 1;15(2):265-78. DOI:

van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiotherapy and Oncology. 2011 Mar 1;98(3):287-91. DOI:

Hodson DI, Krepart GV. Once-monthly radiotherapy for the palliation of pelvic gynecological malignancy. Gynecologic oncology. 1983 Aug 1;16(1):112-6. DOI:

Halle JS, Rosenman JG, Varia MA, Fowler WC, Walton LA, Currie JL. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. International Journal of Radiation Oncology* Biology* Physics. 1986 Nov 1;12(11):1947-50.

Spanos Jr WJ, Wasserman T, Meoz R, Sala J, Kong J, Stetz J. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study. International Journal of Radiation Oncology* Biology* Physics. 1987 Oct 1;13(10):1479-82. DOI:

Spanos Jr WT, Clery M, Perez CA, Grigsby PW, Doggett RS, Poulter CA, Alan DS. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). International Journal of Radiation Oncology* Biology* Physics. 1994 Jul 30;29(5):961-7. DOI:

Spanos Jr WJ, Perez CA, Marcus S, Poulter CA, Doggett RS, Steinfeld AD, Grigsby PW. Effect of rest interval on tumor and normal tissue response—a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). International Journal of Radiation Oncology* Biology* Physics. 1993 Feb 15;25(3):399-403. DOI:

Boulware RJ, Caderao JB, Delclos L, Wharton JT, Peters LJ. Whole pelvis megavoltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancers. International Journal of Radiation Oncology* Biology* Physics. 1979 Mar 1;5(3):333-8. DOI:

Patricio MB, Tavares MA, Guimaraes MF, Belo MC, Vilhena M. Haemostatic and antialgic effects of the 25 MV photon beam concentrated dose in the treatment of carcinoma of the cervix. Journal of surgical oncology. 1987 Feb;34(2):133-5. DOI:

Onsrud M, Hagen B, Strickert T. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri. Gynecologic oncology. 2001 Jul 1;82(1):167-71. DOI:

Halle JS, Rosenman JG, Varia MA, Fowler WC, Walton LA, Currie JL. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. International Journal of Radiation Oncology* Biology* Physics. 1986 Nov 1;12(11):1947-50. DOI:

Mishra SK, Laskar S, Muckaden MA, Mohindra P, Shrivastava SK, Dinshaw KA. Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. Journal of cancer research and therapeutics. 2005 Oct 1;1(4):208. DOI:

Kim DH, Lee JH, Ki YK, Nam JH, Kim WT, Jeon HS, Park D, Kim DW. Short-course palliative radiotherapy for uterine cervical cancer. Radiation oncology journal. 2013 Dec;31(4):216. DOI:

Grigsby PW, Portelance L, Williamson JF. High dose rate (HDR) cervical ring applicator to control bleeding from cervical carcinoma. International Journal of Gynecologic Cancer. 2002 Jan 1;12(1). DOI:

Most read articles by the same author(s)